Valneva begins U.K. approval process for COVID-19 vaccine

By The Science Advisory Board staff writers

French firm Valneva has begun the regulatory submission process to the U.K.'s Medicines and Healthcare products Regulatory Agency for its COVID-19 vaccine candidate, VLA2001.

The candidate is a whole-virus, inactivated, adjuvanted vaccine -- the only one of its kind in clinical trials in Europe, according to the company. The company is conducting a phase III trial for the vaccine and hopes to receive approval for it before the end of the year.

In September 2020, Valneva entered into an agreement with the U.K. government for the option to purchase up to 190 million doses of the vaccine through 2025, it said.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?